Use of chimeric antigen receptor-modified T-cells to treat cancer

US9499629B2 · kind B2 · utility

Assignee

• The Trustees of the University of Pennsylvania · US

Inventors

• Carl H. June · Yeadon, US
• Bruce L. Levine · Cherry Hill, US
• David L. Porter · Springfield, US
• Michael D. Kalos · Philadelphia, US
• Michael C. Milone · Cherry Hill, US

Key dates

• Filing date: Dec 9, 2011
• Grant date: Nov 22, 2016
• Expiry date: Jul 21, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/15071
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.